Enanta Pharmaceuticals (ENTA) Upgraded by Zacks Investment Research to Buy

Enanta Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Enanta Pharmaceuticals Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Enanta Pharmaceuticals traded up $0.73 on Monday, reaching $70.83. 68486 shares of the stock traded hands, compared to its average volume of 139752. Shares of Enanta Pharmaceuticals were trading at $70.83 on Monday. The firm’s 50 day moving average is $54.47 and its 200 day moving average is $49.77.Enanta Pharmaceuticals has a 12 month low of $69.91 and a 12 month high of $71.00. While on yearly highs and lows, Enanta Pharmaceuticals’s today has traded high as $71.00 and has touched $69.91 on the downward trend. See More Analyst Rating at: RATING

Enanta Pharmaceuticals Earnings and What to expect: 

Enanta Pharmaceuticals last announced its earnings data on August 5th, 2021. The biotechnology company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($1.41) by $0.22. The business earned $21.62 million during the quarter, compared to the consensus estimate of $21.87 million. Enanta Pharmaceuticals has generated ($0.89) earnings per share over the last year (($4.15) diluted earnings per share). Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.15) to ($5.82) per share. Enanta Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 22nd, 2021 based off prior year’s report dates.

Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.15) to ($5.82) per share. The P/E ratio of Enanta Pharmaceuticals is -17.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Enanta Pharmaceuticals is -17.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Enanta Pharmaceuticals has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Enanta Pharmaceuticals (ENTA) Moving Average Technical Analysis

5 day Moving Average is $66.07 And 5 day price change is $10.64 (17.68%)  with average volume for 5 day average is 181,360. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $59.51 and 20 day price change is $13.55 (23.66%) and average 20 day moving volume is 139,190. 50 day moving average is $54.47  and 50 day price change is $28.58 ( 67.64%)  and with average volume for 50 days is : 149,050. 200 day moving average is $49.77  and 200 day price change is $28.53 (67.45%)  and with average volume for 200 days is : 144,012.

Other owners latest trading in Enanta Pharmaceuticals :

  • On 10/7/2021 shares held by State of Alaska Department of Revenue were 13,125 which equates to market value of $0.75M and appx 0.00% owners of Enanta Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 61,786 which equates to market value of $2.72M and appx 0.00% owners of Enanta Pharmaceuticals
  • On 8/26/2021 shares held by Comerica Bank were 16,855 which equates to market value of $0.82M and appx 0.00% owners of Enanta Pharmaceuticals
  • In total Institutional ownership equates to There is no enough data Institutional Ownership Percentage for Enanta Pharmaceuticals

See More Analyst Rating at: RATING